A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

Key facts

Sponsor

Janssen Research & Development, LLC

Principal Investigator

Janssen Research & Development, LLC Clinical Trial

Janssen Research & Development, LLC

Intervention

Prizloncabtagene autoleucel (Prizlo-Cel)(biological)

Enrollment

439 enrolled

Eligibility

18 years · All sexes

Timeline

2022 – 2029

Study locations (30)

• City of Hope, Duarte, California, United States
• Colorado Blood Cancer Institute, Denver, Colorado, United States
• University of Iowa Hospital and Clinics, Iowa City, Iowa, United States
• University of Kentucky Medical Center, Lexington, Kentucky, United States
• Rutgers Cancer Institute of New Jersey, Piscataway, New Jersey, United States
• Levine Cancer Institute, Charlotte, North Carolina, United States
• University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
• University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
• Greco Hainesworth Tennessee Oncology Centers for Research, Nashville, Tennessee, United States
• Sarah Cannon Research Institute, Nashville, Tennessee, United States
• St. David's South Austin Medical Center, Austin, Texas, United States
• Texas Transplant Institute, San Antonio, Texas, United States
• Swedish Cancer Institute, Seattle, Washington, United States
• St Vincents Hospital Melbourne, Fitzroy, Australia
• The Alfred Hospital, Melbourne, Australia
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for B-cell non-Hodgkin lymphoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07133997
  Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia
  City of Hope Medical Center
• RECRUITINGPHASE1NCT07361224
  Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion.
  Tel-Aviv Sourasky Medical Center
• RECRUITINGPHASE2NCT07523737
  Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
  Beijing Tongren Hospital
• RECRUITINGPHASE1, PHASE2NCT07283679
  Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
  M.D. Anderson Cancer Center
• RECRUITINGPHASE1, PHASE2NCT07135466
  A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies
  Sheba Medical Center
• ACTIVE NOT RECRUITINGPHASE2NCT07480850
  Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma
  Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• ACTIVE NOT RECRUITINGNCT07480837
  Dynamic Monitoring of Plasma ctDNA for Prognostic Assessment in Patients With B-Cell Non-Hodgkin Lymphoma
  Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• RECRUITINGEARLY PHASE1NCT07376642
  A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
  Suzhou Immunofoco Biotechnology Co., Ltd

See all trials for B-cell non-Hodgkin lymphoma →